LEGN (Legend Biotech) Moat Score: 6/10 (As of Jun. 30, 2026)


LEGN Legend Biotech Corp LEGN
73 GF Score
Price $29.37
GF Value $98.55
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Legend Biotech Moat Score?

Legend Biotech LEGN +2.42% 73 Moat Score is 6 as of Jun. 30, 2026. GuruFocus rates LEGN with a GF Score™ of 73/100 and a GF Value™ of $98.55 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,401 Biotechnology companies, Legend Biotech ranks better than 98.93% on this metric.

Legend Biotech has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Legend Biotech has Narrow Moat: Legend Biotech has a strong narrow moat with valuable intellectual property in cell therapies and robust R&D capabilities. However, it faces intense competition in the biotech sector.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Legend Biotech might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Legend Biotech  (NAS:LEGN) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Legend Biotech Moat Score Related Terms

LEGN vs TVTX, ORKA, CRSP: Moat Score Comparison

For the Biotechnology subindustry, Legend Biotech's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Legend Biotech Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Legend Biotech's Moat Score distribution charts can be found below:

* The bar in red indicates where Legend Biotech's Moat Score falls into.


LEGN
73GF Score
Legend Biotech Corp LEGN
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
Legend Biotech (LEGN) has a Moat Score of 6 as of Jun. 30, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Legend Biotech ranks #15 out of 1401 companies in the Biotechnology industry, placing it in the top 1.1%.
Is Legend Biotech's Moat Score too high?
Legend Biotech's current Moat Score is 6. The Biotechnology industry median Moat Score is 2.00. Legend Biotech's value of 6 is 200% above this industry median. Based on the distribution chart, Legend Biotech ranks #15 out of 1401 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Legend Biotech has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Legend Biotech's Moat Score compare to TVTX and ORKA?
According to the Biotechnology industry distribution chart, Legend Biotech ranks #15 out of 1401 companies for Moat Score. This places Legend Biotech in the top 1% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Legend Biotech's value of 6 is 200% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Legend Biotech's current Moat Score of 6 is 200% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Legend Biotech's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Legend Biotech stock overvalued right now?
Based on GuruFocus' analysis, Legend Biotech (LEGN) is currently considered Possible Value Trap. The stock's GF Value™ is $98.55, compared to a current price of $29.37 — trading 70.2% below its estimated fair value. The current Moat Score is 6 and 200% above the Biotechnology industry median of 2.00. Legend Biotech's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Legend Biotech (LEGN), the current Moat Score is 6 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Legend Biotech (LEGN) Overvalued in 2026?

Based on GuruFocus' analysis, Legend Biotech stock appears to be undervalued. The current stock price of $29.37 is trading 70.2% below its estimated GF Value™ of $98.55. GuruFocus considers Legend Biotech to be Possible Value Trap.

Key valuation signals for LEGN:

  • Moat Score: 6
  • GF Value™: $98.55 vs. price of $29.37 (70.2% below fair value)
  • GF Score™: 73/100 with 2 warning signs
  • Industry Position: 200% above the Biotechnology median (#15 of 1401)

No single metric tells the full story. See the LEGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Legend Biotech Business Description

Other Exchanges 9LB:Germany
Address 2101 Cottontail Lane, Somerset, NJ, USA, 08873
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
73GF Score

Get the complete analysis for LEGN

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.37
Price
$98.55
GF Value